Pranlukast

CHEMBL21333 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

481.5 g/mol

LogP

4.2

Phase

4

Pranlukast is a cysteinyl leukotriene receptor-1 (CysLT1) antagonist that blocks the bronchoconstrictor and pro-inflammatory actions of leukotrienes C4, D4, and E4 in the airways, reducing asthma symptoms including bronchospasm, mucus secretion, and airway eosinophilia. It is used in Japan and other Asian countries for the maintenance treatment of asthma and allergic rhinitis.

Masse moléculaire

481,5000 g/mol

LogP

4,20

TPSA

119,00 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Asthma

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C(Nc1cccc2c(=O)cc(-c3nnn[nH]3)oc12)c1ccc(OCCCCc2ccccc2)cc1

InChI

InChI=1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32)

Molecular Formula

C27H23N5O4

HBD / HBA

2 / 7

Liaisons Rotatives

9

Atomes Lourds

36

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

Pranlukast is a cysteinyl leukotriene receptor-1 (CysLT1) antagonist that blocks the bronchoconstrictor and pro-inflammatory actions of leukotrienes C4, D4, and E4 in the airways, reducing asthma symptoms including bronchospasm, mucus secretion, and airway eosinophilia. It is used in Japan and other Asian countries for the maintenance treatment of asthma and allergic rhinitis.

Yes, Pranlukast is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL21333. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 4887. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Pranlukast sur PillFYI

Structure

Données Clés

Formule: C27H23N5O4

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.